Heron Therapeutics (HRTX) Depreciation & Amortization (CF) (2010 - 2026)

Heron Therapeutics (HRTX) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $529000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 3.99% year-over-year to $529000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 2.96% YoY) and the FY2025 annual result came in at $2.3 million, down 7.44% from the prior year.
• Depreciation & Amortization (CF) slipped to $529000.0 in Q1 2026, from $537000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $791000.0 in Q4 2022 to a low of $529000.0 in Q1 2026.
• A 5-year average of $654764.7 and a median of $671000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) advanced 10.13% — and 2024, when it declined 20.08%.
• Tracing HRTX's Depreciation & Amortization (CF) over 5 years: stood at $791000.0 in 2022, then dropped by 9.61% to $715000.0 in 2023, then slipped by 17.62% to $589000.0 in 2024, then dropped by 8.83% to $537000.0 in 2025, then fell by 1.49% to $529000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $529000.0 (Q1 2026), $537000.0 (Q4 2025), and $615000.0 (Q3 2025), per Business Quant data.